IMP-1088 is primarily investigated for its potential in cancer therapy, particularly as an inhibitor of N-myristoyltransferases (NMTs). By targeting NMTs, it disrupts the myristoylation process, which is crucial for the function and localization of many cancer-related proteins. This disruption can lead to the inhibition of cancer cell growth and survival, making it a promising candidate for the development of novel anticancer drugs. Additionally, its mechanism of action is being explored to overcome resistance to existing therapies, offering a new avenue for treating aggressive or refractory cancers. Furthermore, IMP-1088 is being studied for its potential in treating certain infectious diseases, as NMT enzymes play a key role in the survival of pathogens such as viruses and parasites. Ongoing research aims to evaluate its efficacy and safety in preclinical and clinical settings, potentially leading to more effective anticancer and antimicrobial drugs.